Document is current
Any future updates will be listed below
-
Authors
de Wispelaere, Mélissanne https://orcid.org/0000-0002-0682-3054
Du, Guangyan
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Zhang, Tinghu
Eleuteri, Nicholas A.
Yuan, Jingting C.
Kalabathula, Joann
Nowak, Radosław P. https://orcid.org/0000-0002-0605-0071
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Yang, Priscilla L.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01 CA214608-02)
U.S. Department of Health & Human Services | National Institutes of Health (U19AI109740)
Dana-Farber Cancer Institute Medicinal Chemistry Core
Quadrangle Fund for the Advancement and Seeding of Translational Research at Harvard Medical School
- License Information
-
More Information
Article History
Received: 2 April 2019
Accepted: 12 July 2019
First Online: 1 August 2019
Competing interests
: N.S.G. is an equity holder and scientific advisor for Syros, Gatekeeper, Soltego, C4, B2S, Petra and Aduro companies. N.S.G., G.D., P.L.Y., M.d.W. are inventors on a patent covering the compounds described in this paper. E.S.F is an equity holder and scientific advisor for C4 Therapeutics and Civetta Therapeutics and is a consultant to Novartis, AbbVie, Pfizer, and Deerfield. E.S.F received research funding from Novartis and Astellas not related to this work. The remaining authors declare no competing interests.
